Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Contact us
Business Ethics
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2012
Press release archive
Webcast and presentation
DRUG CANDIDATES
ELND005 - Alzheimer's disease
TT301/302 - inflammation
TT401/402 - diabetes
PRODUCT PIPELINE
View Transition's product pipeline
LATEST NEWS
Transition Announces ELND005 Presentations at the 12th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapies - May 14, 2012
Link to Conference Call on 2012 Third Quarter Results
© 2012 Transition Therapeutics Inc.
